Boehringer Olaf Scholz break ground for innovation center Boehringer Olaf Scholz break ground for innovation center Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Odile Bain Memorial Prize 2021 Odile Bain Memorial Prize 2021 Brilliant early-career scientists in parasitology recognized
sustainably fighting rabies info hub sustainably fighting rabies info hub Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Global mobility Global mobility We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
collaboration-proxygen-molecular-glue-degraders collaboration-proxygen-molecular-glue-degraders Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Advance study vaccinating increased milk production Advance study vaccinating increased milk production [New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Three challenges shape future antiparasitic treatment Three challenges shape future antiparasitic treatment The three key challenges that will shape the future of antiparasitic treatment
Covid Global Support Programm Covid Global Support Programm COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
additional-investment-in-Lyon-Jonage additional-investment-in-Lyon-Jonage Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Classical Swine Fever live vaccine approved in China Classical Swine Fever live vaccine approved in China Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Dr. Hsing-Jung Chen-Engerer Dr. Hsing-Jung Chen-Engerer Prioritizing development with Dr. Hsing-Jung Chen-Engerer
Ivan Blanarik Therapeutic Area Head Respiratory Ivan Blanarik Therapeutic Area Head Respiratory Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Sharing knowledge from our medical device development Sharing knowledge from our medical device development Why do we share some of our work beyond Boehringer for free?
Ukraine Help: In a nine-seater to Poland Ukraine Help: In a nine-seater to Poland Boehringer Ingelheim employee Eugen Pushchyk rescues refugees from Ukraine
Collaboration Boehringer Ingelheim Veeva technology Collaboration Boehringer Ingelheim Veeva technology Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Biberach Biberach The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Annual Results Press Conference Annual Results Press Conference Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Cardiometabolic Diseases Cardiometabolic Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.